Product Description: Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease[1][2][3][4][5].
Applications: COVID-19-immunoregulation
Formula: C19H34N12O11S
References: [1]Maus CE, et al. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005 Feb;49(2):571-7./[2]Garcia-Contreras L, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6./[3]Siddiqi M K, et al. Capreomycin inhibits the initiation of amyloid fibrillation and suppresses amyloid induced cell toxicity[J]. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2018, 1866(4): 549-557./[4]Reisfeld B, et al. A physiologically based pharmacokinetic model for capreomycin[J]. Antimicrobial agents and chemotherapy, 2012, 56(2): 926-934./[5]Le Conte P, et al. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model[J]. Antimicrobial agents and chemotherapy, 1994, 38(12): 2695-2701.
CAS Number: 1405-37-4
Molecular Weight: 638.61
Compound Purity: 99.52
Research Area: Infection; Metabolic Disease; Neurological Disease
Solubility: H2O : ≥ 37 mg/mL
Target: Antibiotic;Bacterial